Fuller & Thaler Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$117M Buy
1,491,004
+25,721
+2% +$1.75M 0.32% 107
2026
Q1
$94.7M Buy
1,465,283
+85,708
+6% +$6.04M 0.32% 112
2025
Q4
$92.8M Buy
1,379,575
+8,391
+0.6% +$564K 0.31% 113
2025
Q3
$101M Buy
1,371,184
+128,176
+10% +$8.51M 0.34% 104
2025
Q2
$64.7M Buy
1,243,008
+112,989
+10% +$6.43M 0.24% 157
2025
Q1
$72.1M Buy
1,130,019
+242,167
+27% +$14.1M 0.28% 128
2024
Q4
$42.4M Buy
887,852
+64,308
+8% +$3.3M 0.16% 199
2024
Q3
$47.1M Buy
823,544
+106,971
+15% +$6.13M 0.19% 173
2024
Q2
$37.5M Buy
716,573
+148,212
+26% +$6.5M 0.16% 189
2024
Q1
$23.1M Buy
568,361
+158,679
+39% +$5.95M 0.1% 217
2023
Q4
$15.1M Buy
409,682
+41,288
+11% +$1.56M 0.08% 237
2023
Q3
$14.1M Buy
368,394
+30,392
+9% +$1.24M 0.08% 217
2023
Q2
$12.2M Buy
+338,002
New +$11.5M 0.07% 229
2022
Q1
Sell
-279,263
Closed -$11.2M 505
2021
Q4
$11.2M Sell
279,263
-3,921
-1% -$146K 0.07% 225
2021
Q3
$11.5M Sell
283,184
-24,649
-8% -$1.03M 0.07% 216
2021
Q2
$14M Sell
307,833
-71,578
-19% -$3.17M 0.09% 190
2021
Q1
$15.8M Buy
379,411
+6,494
+2% +$296K 0.11% 167
2020
Q4
$15.9M Buy
372,917
+7,646
+2% +$275K 0.15% 149
2020
Q3
$9.6M Sell
365,271
-34,135
-9% -$951K 0.12% 169
2020
Q2
$10.7M Buy
399,406
+30,207
+8% +$681K 0.14% 160
2020
Q1
$6.64M Buy
+369,199
New +$7.01M 0.11% 169

Other funds holding HALO

Fuller & Thaler Asset Management's HALO Position: Q2 2026 in Review

Fuller & Thaler Asset Management increased its Halozyme (HALO) stake by 1.8% in Q2 2026, buying an estimated $1.75M and bringing the position to 1,491,004 shares worth $117M. The position accounts for 0.32% of the portfolio, ranked #107.

Fuller & Thaler Asset Management first reported a position in HALO in Q1 2020 and has held it in 21 quarters since. 526 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Fuller & Thaler Asset Management held 1,491,004 shares of Halozyme worth $117M as of Q2 2026.
  • Fuller & Thaler Asset Management bought 25,721 Halozyme shares in Q2 2026, an estimated $1.75M.
  • Halozyme made up 0.32% of Fuller & Thaler Asset Management's portfolio in Q2 2026, its #107 holding.
  • Fuller & Thaler Asset Management first reported a position in Halozyme in Q1 2020 and has held it in 21 quarters since.
  • 526 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.